[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.
[3] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[4] TELANG N. Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 2015;10(6):3840-3846.
[5] ZHANG J, LIU D, FENG Z, et al. MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother. 2016;77:135-141.
[6] GNANT M, HARBECK N, THOMSSEN C. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel). 2011;6(2):136-141.
[7] NIK-ZAINAL S, DAVIES H, STAAF J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47-54.
[8] GOODSPEED A, HEISER LM, GRAY JW, et al. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res. 2016;14(1):3-13.
[9] NAGLE PW, PLUKKER JTM, MUIJS CT, et al. Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol. 2018;53:258-264.
[10] BEN-DAVID U, SIRANOSIAN B, HA G, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560(7718): 325-330.
[11] SCHUTGENS F, CLEVERS H. Human Organoids: Tools for Understanding Biology and Treating Diseases. Annu Rev Pathol. 2020;15:211-234.
[12] LANCASTER MA, KNOBLICH JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014; 345(6194):1247125.
[13] LI M, IZPISUA BELMONTE JC. Organoids - Preclinical Models of Human Disease. N Engl J Med. 2019;380(6):569-579.
[14] SATO T, VRIES RG, SNIPPERT HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262-265.
[15] 董研博,王健,郑梦竹,等.类器官研究进展及应用[J].中国药理学与毒理学杂志,2019,33(2):152-160.
[16] SATO T, CLEVERS H. SnapShot: Growing Organoids from Stem Cells. Cell. 2015;161(7):1700-1700.e1.
[17] HUCH M, GEHART H, VAN BOXTEL R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015; 160(1-2):299-312.
[18] NADKARNI RR, ABED S, DRAPER JS. Organoids as a model system for studying human lung development and disease. Biochem Biophys Res Commun. 2016;473(3):675-682.
[19] MORIZANE R, BONVENTRE JV. Kidney Organoids: A Translational Journey. Trends Mol Med. 2017;23(3):246-263.
[20] SEINO T, KAWASAKI S, SHIMOKAWA M, et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22(3):454-467.e6.
[21] CARRANZA-ROSALES P, GUZMÁN-DELGADO NE, CARRANZA-TORRES IE,et al. Breast Organotypic Cancer Models. Curr Top Microbiol Immunol. 2018 Mar 20. doi: 10.1007/82_2018_86. Online ahead of print.
[22] KASAGI Y, CHANDRAMOULEESWARAN PM, WHELAN KA, et al. The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. Cell Mol Gastroenterol Hepatol. 2018;5(3):333-352.
[23] MAZZUCCHELLI S, PICCOTTI F, ALLEVI R, et al. Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer. Biol Proced Online. 2019;21:12.
[24] TUVESON D, CLEVERS H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952-955.
[25] VLACHOGIANNIS G, HEDAYAT S, VATSIOU A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926.
[26] SATO T, STANGE DE, FERRANTE M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141(5):1762-1772.
[27] BOJ SF, HWANG CI, BAKER LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1-2):324-338.
[28] PARK JW, LEE JK, PHILLIPS JW, et al. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci U S A. 2016;113(16):4482-4487.
[29] BROUTIER L, MASTROGIOVANNI G, VERSTEGEN MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424-1435.
[30] FRANCIES HE, GARNETT MJ. What role could organoids play in the personalization of cancer treatment? Pharmacogenomics. 2015; 16(14):1523-1526.
[31] ASTASHKINA A, GRAINGER DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev. 2014;69-70:1-18.
[32] ZHANG L, ZHAO J, LIANG C, et al. A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP. Drug Deliv. 2017;24(1):1453-1459.
[33] KARKI R, MAN SM, MALIREDDI RKS, et al. NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer. Nature. 2016;540(7634):583-587.
[34] YOSHIDA T, SOPKO NA, KATES M, et al. Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells. Oncotarget. 2018;9(13):11060-11070.
[35] GAO D, VELA I, SBONER A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176-187.
[36] DATE S, SATO T. Mini-gut organoids: reconstitution of the stem cell niche. Annu Rev Cell Dev Biol. 2015;31:269-289.
[37] SACHS N, DE LIGT J, KOPPER O, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172(1-2): 373-386.e10.
[38] ROSKOSKI R JR. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74.
[39] LEE CY, LIN Y, BRATMAN SV, et al. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res. 2014;74(1):341-352.
[40] DROST J, CLEVERS H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407-418.
[41] 刘宏飞,陈晓红,黄志刚,等.类器官和人源性肿瘤组织异种移植模型在肿瘤研究中的应用[J].中国比较医学杂志,2019,29(3): 103-108.
[42] WEEBER F, OOFT SN, DIJKSTRA KK, et al. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. Cell Chem Biol. 2017; 24(9): 1092-1100.
[43] DAI X, XIANG L, LI T, et al. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016;7(10):1281-1294.
[44] NAYAK B, BALACHANDER GM, MANJUNATH S, et al. Tissue mimetic 3D scaffold for breast tumor-derived organoid culture toward personalized chemotherapy. Colloids Surf B Biointerfaces. 2019;180:334-343.
[45] COE BP, WITHERSPOON K, ROSENFELD JA, et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat Genet. 2014;46(10):1063-1071.
[46] GOSSAGE L, EISEN T, MAHER ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55-64.
[47] ROELOFS C, HOLLANDE F, REDVERS R, et al. Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer. Biochem Soc Trans. 2019;47(1):109-117.
[48] SCHMIDT M, THOMSSEN C, UNTCH M. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis. Oncol Res Treat. 2016;39(3): 102-110.
[49] ALI HR, RUEDA OM, CHIN SF, et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 2014;15(8):431.
[50] KOLEDOVA Z. 3D Coculture of Mammary Organoids with Fibrospheres: A Model for Studying Epithelial-Stromal Interactions During Mammary Branching Morphogenesis. Methods Mol Biol. 2017;1612:107-124.
[51] CHATTERJEE S, BHAT V, BERDNIKOV A, et al. Paracrine Crosstalk between Fibroblasts and ER+ Breast Cancer Cells Creates an IL1β-Enriched Niche that Promotes Tumor Growth. iScience. 2019;19: 388-401.
[52] UMESH V, RAPE AD, ULRICH TA, et al. Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling. PLoS One. 2014;9(7):e101771.
[53] BUESS M, NUYTEN DS, HASTIE T, et al. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol. 2007;8(9):R191.
[54] PARK SE, GEORGESCU A, HUH D. Organoids-on-a-chip. Science. 2019; 364(6444):960-965.
[55] SONTHEIMER-PHELPS A, HASSELL BA, INGBER DE. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019;19(2):65-81.
[56] CHEN MB, WHISLER JA, FRÖSE J, et al. On-chip human microvasculature assay for visualization and quantification of tumor cell extravasation dynamics. Nat Protoc. 2017;12(5):865-880.
[57] SHIRURE VS, BI Y, CURTIS MB, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. Lab Chip. 2018;18(23):3687-3702.
[58] WALSH AJ, COOK RS, SANDERS ME, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014;74(18):5184-5194.
[59] DEKKERS JF, WHITTLE JR, VAILLANT F, et al. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. J Natl Cancer Inst. 2020;112(5):540-544.
[60] PARK S, BRUGIOLO M, AKERMAN M, et al. Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis. Cell Rep. 2019;29(9):2672-2688.e7.
[61] CHEUNG KJ, GABRIELSON E, WERB Z, et al. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell. 2013; 155(7):1639-1651.
[62] ZUMWALDE NA, HAAG JD, SHARMA D, et al. Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate. Cancer Prev Res (Phila). 2016;9(4):305-316.
[63] 吴宇琪.乳腺癌的体外类器官培养和个性化药物选择[D].北京:北京协和医学院中国医学科学院;清华大学医学部;北京协和医学院, 2018.
[64] QU Y, HAN B, GAO B, et al. Differentiation of Human Induced Pluripotent Stem Cells to Mammary-like Organoids. Stem Cell Reports. 2017;8(2):205-215.
[65] CHOU JL, SHEN ZX, STOLFI RL, et al. Effects of extracellular matrix on the growth and casein gene expression of primary mouse mammary tumor cells in vitro. Cancer Res. 1989;49(19):5371-5376.
[66] YOSHIDA GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1):4. |